Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)

Proposals for the classification of the myelodysplastic syndromes

John M. Bennett, Daniel Catovsky, MT Daniel et al. · British Journal of Haematology · 1982 · 3.7K citations

Hematological Malignancy, Hematology, Diagnosis +6

Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndromes

Saroj Vadhan‐Raj, Michael J. Keating, A LeMaistre et al. · New England Journal of Medicine · 1987 · 637 citations

Immunology, Pathology, Immunotherapy +16

Myelodysplastic syndromes: a scoring system with prognostic significance

G J Mufti, Jasper Stevens, David Oscier et al. · British Journal of Haematology · 1985 · 517 citations

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

Ellin Berman, Glenn Heller, J Santorsa et al. · Blood · 1991 · 369 citations · Full text

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Pascal Morel, Mohamed Hebbar, J L Laï et al. · PubMed · 1993 · 303 citations